A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

ClinicalTrials.gov ID: NCT02608697

Public ClinicalTrials.gov record NCT02608697. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Study identification

NCT ID: NCT02608697
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Catabasis Pharmaceuticals; Industry
Enrollment: 153 participants

Conditions and interventions

Conditions

Hypercholesterolemia

Interventions

Atorvastatin Drug
CAT-2054 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 74 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2015
Primary completion: Apr 30, 2016
Completion: May 31, 2016
Last update posted: Jun 19, 2017

2015 – 2016

United States locations

U.S. sites: 34
U.S. states: 17
U.S. cities: 31

Facility	City	State	ZIP	Site status
Not listed	Muscle Shoals	Alabama	35662	—
Not listed	Huntington Park	California	90255	—
Not listed	Lomita	California	90717	—
Not listed	Los Angeles	California	90057	—
Not listed	Brooksville	Florida	34601	—
Not listed	Hialeah	Florida	33012	—
Not listed	Jupiter	Florida	33458	—
Not listed	Pembroke Pines	Florida	33026	—
Not listed	Winter Park	Florida	32792	—
Not listed	Chicago	Illinois	60607	—
Not listed	Evanston	Illinois	60201	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Kansas City	Kansas	66160	—
Not listed	Louisville	Kentucky	40213	—
Not listed	Auburn	Maine	04210	—
Not listed	Troy	Michigan	48098	—
Not listed	Las Vegas	Nevada	89123	—
Not listed	New York	New York	10029	—
Not listed	Rochester	New York	14609	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Cincinnati	Ohio	45227	—
Not listed	Cincinnati	Ohio	45246	—
Not listed	Columbus	Ohio	43213	—
Not listed	Franklin	Ohio	45005	—
Not listed	Lyndhurst	Ohio	44124	—
Not listed	Marion	Ohio	43302	—
Not listed	Willoughby Hills	Ohio	44094	—
Not listed	Mt. Pleasant	South Carolina	29464	—
Not listed	Summerville	South Carolina	29485	—
Not listed	Houston	Texas	77036	—
Not listed	Houston	Texas	77074	—
Not listed	Orem	Utah	84058	—
Not listed	Richmond	Virginia	23294	—
Not listed	Olympia	Washington	98502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02608697, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 19, 2017 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02608697 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →